¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"visual method"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • visual evoked potential
    ½Ã°¢À¯¹ßÀüÀ§
  • visual evoked response
    ½Ã°¢À¯¹ß¹ÝÀÀ
  • visual field
    ½Ã¾ß
  • visual field defect
    ½Ã¾ß°á¼Õ
  • visual field examination
    ½Ã¾ß°Ë»ç
  • visual hallucination
    ȯ½Ã
  • visual image
    ½Ã°¢»ó
  • visual infancy
    ¿µ¾ÆÇü½Ã°¢
  • visual inspection
    ½ÃÁø
  • visual line
    ½Ã(°¢)¼±
  • visual maturity
    ½Ã°¢¼º¼÷µµ
  • visual memory
    ½Ã°¢±â¾ï
  • visual nystagmus
    ½Ã°¢´«¶³¸², ½Ã°¢¾ÈÁø
  • visual organ
    ½Ã°¢±â°ü
  • visual pathway
    ½Ã°¢°æ·Î
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • visual hallucination
    ȯ½Ã, º¸ÀÓȯ°¢
  • visual image
    ½Ã°¢»ó
  • visual infancy
    ¿µ¾ÆÇü½Ã°¢
  • organic visual loss
    ±âÁú½Ã°¢»ó½Ç
  • visual line
    ½Ã°¢¼±
  • visual maturity
    ¼º¼÷½Ã°¢
  • visual memory
    ½Ã°¢±â¾ï
  • visual nystagmus
    ½Ã°¢´«¶³¸²
  • visual organ
    ½Ã°¢±â°ü
  • visual pathway
    ½Ã°¢°æ·Î
  • visual pigment
    ½Ã»ö¼Ò
  • visual purple
    ½Ã»ö¼Ò
  • visual evoked potential
    ½Ã°¢À¯¹ßÀüÀ§
  • visual receptor
    ½Ã°¢¼ö¿ëü, °¨±¤Ã¼
  • visual red
    (¢¡rhodopsin) ½ÃÈ«, ·Îµ½½Å
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Quellung method
    ÆØÃ¢¹ý(ø³óìÛö).
  • Quellung method
    ÆØÃ¢¹ý(ø³óìÛö).
  • Rothera method
    ·ÎÅ×¶ó¹ý
  • Schoenheimer-Sperry method
    ½¨ÇÏÀ̸Ó-½ºÆä¸® ¹æ¹ý
  • Shihabi-Bishop method
    ½ÃÇϺñ-ºñ¼ó ¹æ¹ý
  • Spinner method
    ½ºÇdzÊ(¹æ)¹ý
  • Tietz-Fiereck method
    ƼÂÅ-ÇÇ·º¹æ¹ý
  • Valsalva method
    ¹ß»ì¹Ù¹ý
  • Wintrobe hematocrit method
    À©Æ®·ÎºêÇ츶ÅäÅ©¸®Æ®¹ý
  • Zebra-stripe imaging method
    ¾ó·è¸» ¹«´Ì ¿µ»ó ¹æ¹ý
  • Zeeman correction method
    Áö¸¸±³Á¤¹ý
  • acid hematin method
    »êÇ츶ƾ¹ý(¡­Ûö).
  • acquisition method
    ȹµæ ¹æ¹ý
  • activated sludge method
    Ȱ¼º¿À´Ï¹ý(Ì·ËÛËçËöËÑ).
  • actuarial method
    º¸ÇèÅë°è¹ý
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • visual agnosis
    ½Ã°¢½ÇÀÎ(ãÊÊÆã÷ìã)
  • visual aids
    ½Ã·Âº¸Á¶±â
  • visual allachesthesia
    À̼ҽð¢
  • visual angle
    ½Ã°¢(ãÊÊÇ)
  • visual angle
    ½Ã°¢(ãÊÊÇ).
  • visual aphasia
    ½Ã°¢¼º ½Ç¾îÁõ(¡­ã÷åÞñø).
  • visual aphasia
    ½Ã°¢¼º ½Ç¾îÁõ(¡­ã÷åÞñø)
  • visual area
    ½Ã°¢¿µ¿ª(çÐæ´).
  • visual association area
    ½Ã°¢¿¬ÇÕ¿µ¿ª
  • visual aura
    ½Ã°¢ÀüÁ¶(ãÊÊÆîñð¼).
  • visual aura
    ½Ã°¢ÀüÁ¶(ãÊÊÆîñð¼)
  • visual axis
    ½ÃÃà(ãÊõî)
  • visual axis
    ½ÃÃà(ãÊõî), ½Ã¼±(ãÊàÊ).
  • visual cell
    ½Ã¼¼Æ÷
  • visual cell
    ½Ã°¢¼¼Æ÷, ½Ã¼¼Æ÷(ãÊá¬øà).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Folch method
    ÆúÃ÷¹ý(Ûö)
  • Folin method
    Æú¸°¹ý(Ûö)
  • Folin-Wu method
    Æú¸°-¿ì¹ý(Ûö)
  • gaseous exposure method
    °³½º ³ëÃâ¹ý(ÖÚõóÛö)
  • Gilbert-Maxam method
    ±æ¹öÆ®-¸Æ»ï¹ý(Ûö)
  • gradient-flow method
    ±¸¹è(ÎþÛÕ)-È帧¹ý(Ûö)
  • heavy atom method
    Áß¿øÀÚ¹ý(ñìê«í­Ûö)
  • high-temperature-short-time method
    °í¿Â ´Ü½Ã°£¹ý(ÍÔè®Ó­ãÁÊàÛö)
  • isotope derivative method
    µ¿À§¿ø¼ÒÀ¯µµÃ¼¹ý(ÔÒêÈêªáÈë¯Óôô÷Ûö)
  • jump method
    ¶Ù±â ¹æ¹ý(Û°Ûö)
  • Kjeldahl method
    Ű¿¤´Þ¹ý(Ûö)
  • label triangulation method
    Ç¥Áö»ï°¢È­¹ý(øöò½ß²ÊÇûùÛö)
  • Lowry method
    ·Î¿ì¸®¹ý(Ûö)
  • low-temperature heat method
    Àú¿Â¿­¹ý(î¸è®æðÛö)
  • LTH method
    LTH¹ý(Ûö)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
BET benign epithelial tumor; bleeding esophageal varix; Brunauer-Emmet-Teller [method]
BLB Baker-Lima-Baker [mask]; Bessey-Lowry-Brock [method or unit]; black light bulb; Boothby-Lovelace-Bul...
BSAM basic sequential access method
CAM calf aortic microsome; cell adhesion molecule; cell-associating molecule; chorioallantoic membrane; ...
CPM central pontine myelinosis; chlorpheniramine maleate; continuous passive motion; critical path metho...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PCR polimerase chain reaction method
SCAM substituted cysteine accessibility method
BVRT Benton Visual Retention Test
BCVA Best corrected visual acuity
BSCVA Best spectacle corrected visual acuity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Denis-Leche's method
    µ¥´Ï½º-·¹Ä¡¹ý
    Àü Ȳȭ¹°ÀÇ °ËÃâ¹ýÀ¸·Î, »êÀ» °¡ÇØ ºÎÆÐÇÑ ´Ü¹éÁúÀ» Á¦°ÅÇÏ°í ¿°È­ ¹Ù·ý¿¡ ÀÇÇØ ħÀü °ÇÁ¶½ÃŲ ÈÄ Äª·®ÇÑ´Ù.
  • diffusion method
    È®»ê¹ý
  • direct method
    Á÷Á¢¹ý
    ȯÀÚÀÇ ±¸°­³»¿¡¼­ ¿Î½º Á¶°¢ÇÏ¿© ³³ ¿øÇüÀ» ¾ò¾î ¸Å¸ôÇϰí ÁÖÁ¶ÇÏ¿© Àη¹À̳ª Ä¡°ü º¸Ã¶¹°À» ¾ò´Â ¹æ¹ýÀÌ´Ù.
  • discomfort with this imaging method
    ÃÔ¿µ½Ã ºÒÆí°¨
  • double investing method
    ÀÌÁß ¸Å¸ô¹ý
  • draining method
    ¹è³ó¹ý, È긮´Â ¹æ¹ý
    »óó, ±Ë¾ç, °øµ¿¿¡¼­ ¾×ü³ª ¹è¼³¹°À» ü°èÀûÀ¸·Î ¹èÃâ½ÃŰ´Â °Í.
  • dye dilution method
    »ö¼Ò Èñ¼®¹ý
  • electromyogram biofeedback method
    ±ÙÀüµµ ¹ÙÀÌ¿ÀÇǵå¹é¹ý
    ¹ÙÀÌ¿ÀÆÐµå¹éÀÇ ÁöÇ¥·Î ±ÙÀüµµ¸¦ »ç¿ëÇÏ´Â °ÍÀÌ°í ±Ù·Â Áõ°­ ÈÆ·Ã°ú ±Ù ÀÌ¿Ï ÈÆ·Ã°ú´Â ÀüÇô ¹Ý´ëÀÇ Ä¡·á¹ýÀ¸·Î ÇÔ²² ÀÌ¿ëµÈ´Ù. ±Ù·Â Áõ°­ ÈÆ·ÃÀ¸·Î¼­´Â ¸»ÃÊ½Å°æ ¸¶ºñ, ³úÁ¹Áß, ³ú¼º ¸¶ºñ µî¿¡ »ç¿ëµÇ°í ±ÙÀÌ¿Ï ÈÆ·ÃÀ¸·Î¼­´Â »ç°æ µî¿¡ »ç¿ëµÈ´Ù.
  • expansion method
    ÆØÃ¢ ¹æ¹ý
    ¸Å¸ôÀçÀÇ °æÈ­ ÆØÃ¢, °¡¿­ ÆØÃ¢À» ÀÌ¿ëÇϰųª ¸ðÇü Àç·áÀÇ °æÈ­ ÆØÃ¢À» ÀÌ¿ëÇÏ´Â ¹æ¹ýÀÌ´Ù.
  • fast gradient recalled echo method
    °í¼Ó °æ»ç ȸº¹ ¿¡ÄÚ ±â¹ý
  • flash method
    ¿ìÀ¯ ¼Òµ¶¹ý
    ¿ìÀ¯¸¦ 80¡É±îÁö ±Þ¼ÓÈ÷ °¡¿­ÇÑ ÈÄ¿¡ ±Þ¼ÓÈ÷ 5¡É·Î ³»¸®´Â ¸ê±Õ¹ý.
  • functional jaw orthopedic method
    ±â´ÉÀû ¾Ç±³Á¤¹ý
  • immunofluorescence method
    ¸é¿ª Çü±¤¹ý
    Ç×ü³ª Ç׿ø¿¡ Ç÷ç¿À·¹¼¼ÀÎÀ̳ª ·Î´Ù¹Î°ú °°Àº Çü±¤ »ö¼Ò¸¦ Ç¥ÁöÇÑ °ÍÀ» »ç¿ëÇÏ¿© ü¾×°ú Á¶Á÷ µî¿¡ Á¸ÀçÇÏ´Â Ç׿ø ¶Ç´Â Ç×ü¸¦ °ËÃâÇÏ´Â ¹æ¹ý. Ç×ü¸¦ Ç¥ÁöÇÏ´Â °æ¿ì¿¡´Â ´ë°³ Çü±¤ Ç×ü¹ýÀ̶ó°í ºÎ¸¥´Ù. Á÷Á¢¹ý°ú °£Á¢¹ýÀÇ 2°¡Áö ¹æ¹ýÀÌ Àִµ¥, Çü±¤ Ç×üÀÇ °æ¿ì¸¦ ¸»Çϸé Á÷Á¢¹ýÀº Á¶Á÷ ¼Ó¿¡ Á¸ÀçÇÏ´Â Ç׿ø¿¡ ´ëÇÏ¿© ƯÀÌÇÏ°Ô °áÇÕÇÏ´Â Çü±¤ Ç¥Áö Ç×ü¸¦ ¾ãÀº Á¶Á÷ ÀýÆí¿¡ ¹ÝÀÀ½Ã۰í, ±× ÀýÆíÀ» Àß ¾Ä¾î¼­ Çü±¤Çö¹Ì°æÀ¸·Î °üÂûÇϸé Á¶Á÷ ¼ÓÀÇ Ç׿ø°ú °áÇÕÇÑ Çü±¤ Ç×ü°¡ Çü±¤À» ¹ßÇϹǷΠ±× Ç׿øÀÇ Á¸À縦 ¾Ë ¼ö ÀÖ´Ù. °£Á¢¹ýÀº ¸ÕÀú Á¶Á÷ ÀýÆí ¼ÓÀÇ Ç׿ø°ú ÀÌ¿¡ ´ëÀÀÇÏ´Â ¹«Ç¥Áö Ç×ü¸¦ ¹ÝÀÀ½ÃŲ ÈÄ¿¡ ¾Ä°í, ¹«Ç¥Áö Ç×ü¿Í ƯÀÌÇÏ°Ô ¹ÝÀÀÇϴ ǥÁö Ç×ü¸¦ ¹ÝÀÀ½ÃÄѼ­ ¾ÄÀº ´ÙÀ½ Çü±¤Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© Ç׿øÀÇ Á¸À縦 °£Á¢ÀûÀ¸·Î °ËÃâÇÏ´Â ¹æ¹ýÀ¸·Î¼­ Á÷Á¢¹ý¿¡ ºñÇØ Çü±¤·®ÀÌ Áõ´ëÇϹǷΠ°ËÃâ¿¡ ¿ëÀÌÇÏ´Ù.
  • indirect method
    °£Á¢¹ý
    䵿ÇÑ Àλ󿡼­ Á¦ÀÛµÈ ¸ðÇü»ó¿¡¼­ Ä¡°ü ¼öº¹¹°À» Á¦ÀÛÇÏ´Â ¹æ¹ý.
  • indirect-direct method inlay
    Á÷Á¢ °£Á¢¹ý Àη¹ÀÌ
    Á÷Á¢¹ý°ú °£Á¢¹ýÀ» º´¿ëÇÏ¿© ¸¸µç Àη¹ÀÌ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
visual threshold Threshold of visual sensation, the minimal light intensity evoking a visual sensation.
Synonym: achromatic threshold, minimum light threshold.
(05 Mar 2000)
visual violet A visual pigment, composed of 11-cis-retinal bound to an opsin, found in the cones of the retina.
Synonym: visual violet.
Origin: G. Ion, violet, + ops, eye, + -in
(05 Mar 2000)
visual yellow The orange retinaldehyde resulting from the action of light on the rhodopsin of the retina, which converts the 11-cis-retinal component of the rhodopsin to all-trans-retinal plus opsin.
Synonym: trans-retinal, visual yellow.
(05 Mar 2000)
primary visual area Area of the occipital lobe concerned with vision.
(12 Dec 1998)
primary visual cortex See: visual cortex.
(05 Mar 2000)
secondary visual area Area of the occipital lobe concerned with vision.
(12 Dec 1998)
secondary visual cortex See: visual cortex.
(05 Mar 2000)
evoked potentials, visual The electric response evoked in the cerebral cortex by visual stimulation or stimulation of the visual pathways.
(12 Dec 1998)
unformed visual hallucination Hallucination composed of sparks, lights, or bursting spheres of light.
(05 Mar 2000)
formed visual hallucination <psychiatry> Hallucination composed of scenes, often landscapes.
(05 Mar 2000)
functional visual loss An apparent loss of visual acuity or visual field with no substantiating physical signs; often due to a natural concern about visual loss combined with suggestibility and a fear of the worst; best treated with reassurance.
(05 Mar 2000)
Abbott's method A method of treatment of scoliosis by use of a series of plaster jackets applied after partial correction of the curvature by external force.
(05 Mar 2000)
Abell-Kendall method A standard method for estimation of total serum cholesterol involving saponification of cholesterol ester by hydroxide, extraction with petroleum ether, and colour development with acetic anhydride-sulfuric acid; the method avoids interference by bilirubin, protein, and haemoglobin.
(05 Mar 2000)
activated sludge method A method of sewage disposal in which the sewage is treated with 15% bacterially active, liquid sludge, which is produced by repeated vigorous aeration of fresh sewage to form floccules or sediment; when this flocculation process is complete, the resulting activated sludge contains large numbers of bacteria, together with yeasts, molds, and protozoa, which actively effect the oxidation of organic compounds; this mixture is piped to a sedimentation tank, the effluent from which is completely treated sewage.
(05 Mar 2000)
Altmann-Gersh method The method of rapidly freezing a tissue and dehydrating it in a vacuum.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á